LUZU Drug Patent Profile

When do Luzu patents expire, and what generic alternatives are available?

Luzu is a drug marketed by Bausch and is included in one NDA. There are four patents protecting this drug.

This drug has thirty-one patent family members in seven countries.

The generic ingredient in LUZU is luliconazole. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the luliconazole profile page.

DrugPatentWatch^® Generic Entry Outlook for Luzu

Luzu was eligible for patent challenges on November 14, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 28, 2034. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for LUZU

International Patents:	31
US Patents:	4
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LUZU

US Patents and Regulatory Information for LUZU

LUZU is protected by four US patents.

This potential generic entry date is based on patent 8,980,931.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	LUZU	luliconazole	CREAM;TOPICAL	204153-001	Nov 14, 2013		RX	Yes	Yes	9,012,484		Y	Y
Bausch	LUZU	luliconazole	CREAM;TOPICAL	204153-001	Nov 14, 2013		RX	Yes	Yes	8,980,931		Y
Bausch	LUZU	luliconazole	CREAM;TOPICAL	204153-001	Nov 14, 2013		RX	Yes	Yes	9,453,006			Y
Bausch	LUZU	luliconazole	CREAM;TOPICAL	204153-001	Nov 14, 2013		RX	Yes	Yes	9,199,977		Y	Y

International Patents for LUZU

When does loss-of-exclusivity occur for LUZU?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Japan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LUZU around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	980055
China	104619703	Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal
Australia	6319296
Taiwan	450969
China	104284662

LUZU Market Analysis and Financial Projection

Last updated: April 25, 2026

LUZU (luliconazole): Investment Scenario and Fundamentals Analysis

What is LUZU and what assets drive its value?

LUZU is a topical antifungal drug product containing luliconazole. In the U.S., it is marketed as:

• LUZU® (luliconazole) 1% cream
• Indication (U.S.): treatment of tinea pedis (athlete’s foot) caused by Trichophyton rubrum (label scope is product- and jurisdiction-specific).

The investment case for LUZU is shaped by three fundamentals:

1. Indication scope and durability (who it treats, and how long it remains the standard choice).
2. Competitive intensity in topical azoles (price pressure, formulary preference, and substitution).
3. Patent and exclusivity runway (generic entry risk and authorized generic pathways).

Which ownership and commercialization pathways matter for valuation?

Value depends on whether the asset sits in an active commercialization portfolio versus a legacy brand with shrinking demand. For LUZU, the key investor question is whether sales are supported by:

• continuing dermatology or pharmacy channel access,
• contracting and payer uptake,
• and defensible product positioning versus cheaper generic topical azoles.

Because LUZU is a topical azole class drug, its economics typically hinge on channel pricing and differentiation, not clinical re-invention.

---

How do market fundamentals look for luliconazole in topical antifungals?

What is the core demand engine?

Topical antifungal demand in dermatology is driven by:

• prevalence of tinea pedis and recurrent athlete’s foot,
• prescription versus OTC shift dynamics (some mild cases move to OTC),
• and adherence to topical regimens (cream use patterns).

LUZU’s demand is therefore sensitive to:

• payer controls on dermatology prescriptions,
• provider prescribing habits for first-line topical azoles,
• and switching to lower-cost therapeutics when formularies tighten.

What is the competitive set and what does it do to pricing?

In topical antifungals, competitive forces usually include:

• competing branded topical azoles (where present),
• and multiple generic topical azoles and antifungals.

For investor framing, the relevant impact is not “does luliconazole work,” it is whether the product can sustain:

• net price after rebates,
• volume after formulary displacement,
• and share after generic entry or parallel private-label substitution.

Topical azoles typically exhibit faster pricing normalization once generics are available, with survival dependent on managed care positioning and prescriber familiarity.

---

What is the patent and exclusivity risk profile?

Where do patents typically sit for topical antifungals like luliconazole?

For small-molecule antifungals, patent families generally fall into:

• compound and salt/crystal form claims,
• formulation and dosing vehicle claims (relevant in topical products),
• process claims for manufacture,
• and method-of-use or new formulation improvements.

The investor-facing issue is whether LUZU is exposed to:

• early generic launch due to expiring composition or method patents,
• workable “design-around” through formulation changes,
• or authorized generics once exclusivity ends.

What exclusivity signals investment outcomes?

Exclusivity outcomes depend on whether the product is protected by:

• regulatory exclusivity tied to approvals,
• or additional protection from later-described formulations or uses.

For a topical antifungal, the most material value driver is whether there is late-cycle, non-obvious formulation protection that delays generic substitution and preserves pricing.

---

Investment scenario: base case, down case, and upside case

Base case: managed erosion with stable remaining niche share

A realistic base case for a topical antifungal brand is:

• modest volume resilience if prescribers keep it for specific patient segments or payer-approved indications,
• net price compression as generic topical azoles anchor lower pricing,
• gradual brand share normalization without new clinical differentiation.

What to watch: net sales trends for LUZU and pharmacy vs prescription channel mix, because channel access affects discounting and rebate intensity.

Down case: generic-driven volume and price collapse

A down case occurs when:

• key patents and exclusivity end,
• generics launch with rapid uptake,
• and formularies switch preferred status toward lowest-cost alternatives.

For topical azoles, the down-case dynamic often looks like:

• steep volume decline after generics,
• immediate net price compression,
• and increased promotional spend without commensurate share recovery.

What to watch: gross-to-net ratio, changes in average selling price, and the speed of share transfer to generics.

Upside case: durable contracting plus clinical or formulary advantage

Upside requires a reason to pay more for luliconazole than competing generics, such as:

• superior tolerability outcomes in real-world use for certain skin types or patient adherence,
• payer coverage that keeps it on formularies as a preferred option,
• or differentiation that supports slower switching.

What to watch: payer formulary updates, dermatology guideline alignment, and claims of real-world persistence.

---

Fundamentals scorecard (investment lens)

Fundamental	What matters for LUZU	Expected impact on value
Indication durability	Tinea pedis scope and label breadth in core markets	Drives baseline demand and refill behavior
Competitive pricing	Generic topical azoles anchor cost	Limits net price and share once switched
Managed care access	Preferred formulary status and rebate levels	Determines volume retention and gross-to-net
Patent/exclusivity runway	Composition/formulation protection and regulatory exclusivity	Sets timing of generic displacement risk
Channel strategy	Rx vs OTC substitution and pharmacy stocking	Impacts sustained prescription flow

---

What does diligence require for a decision-ready view?

For an investment or R&D decision, diligence should operationalize the following checks:

• Commercial traction: net sales trend, geographic mix, and payer-driven product mix.
• Contracting posture: gross-to-net changes and rebate escalation patterns.
• Competitive mapping: timing of generic entries and uptake against formulary switches.
• Protection stack: remaining patent term by family and whether any later formulation improvements delay entry.

---

Key Takeaways

• LUZU’s economics are mainly driven by formulary access and pricing discipline, not clinical novelty, because topical antifungals face rapid substitution pressure.
• Patent and exclusivity runway is the gating item: once composition or method barriers fall, volume tends to move quickly to generic topical azoles.
• Base case is typically erosion with niche persistence if contracting keeps LUZU on formularies; down case is generics-driven collapse; upside requires payer differentiation or durable coverage that slows switching.
• The highest-signal diligence metrics are gross-to-net, net sales trend slope, and speed of generic share transfer.

---

FAQs

1) Is LUZU positioned for long-term growth?

The topical antifungal segment usually matures quickly once generics dominate. Growth depends on maintaining payer access and resisting switching through the protection stack and contracting.

2) What most often breaks the investment case in topical antifungals?

A key patent or exclusivity expiration that enables rapid generic uptake, followed by formulary displacement and net price normalization.

3) How does gross-to-net analysis inform LUZU’s stability?

Rising rebates and discounts can indicate increasing payer leverage and pressure on net price, often preceding share erosion.

4) What competition matters most for LUZU valuation?

Competing low-cost topical azoles and generic products that can become default formulary options, especially those available with strong pharmacy purchasing economics.

5) What would indicate an upside scenario for LUZU?

Sustained preferred formulary placement and evidence of slower switching than expected, paired with stable net price trends despite competitive launches.

---

References (APA)

[1] FDA. (n.d.). LUZU (luliconazole) prescribing information / label. U.S. Food and Drug Administration.
[2] FDA. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). U.S. Food and Drug Administration.
[3] FDA. (n.d.). Drug Approval Packages and review documents for luliconazole. U.S. Food and Drug Administration.